Pharmagreen Biotech (Pharmagreen Biotech) FCF Margin % : 800.00% (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharmagreen Biotech's Free Cash Flow for the three months ended in Jun. 2023 was $0.01 Mil. Pharmagreen Biotech's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Pharmagreen Biotech's FCF Margin % for the quarter that ended in Jun. 2023 was 800.00%.

As of today, Pharmagreen Biotech's current FCF Yield % is -29.46%.

The historical rank and industry rank for Pharmagreen Biotech's FCF Margin % or its related term are showing as below:

PHBI' s FCF Margin % Range Over the Past 10 Years
Min: -6850 Med: 0 Max: 0
Current: -6850

PHBI's FCF Margin % is ranked worse than
98.73% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.12 vs PHBI: -6850.00

Pharmagreen Biotech FCF Margin % Historical Data

The historical data trend for Pharmagreen Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech FCF Margin % Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

FCF Margin %

Get a 7-Day Free Trial

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-3,400.00	800.00

Competitive Comparison of Pharmagreen Biotech's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's FCF Margin % falls into.

Pharmagreen Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pharmagreen Biotech's FCF Margin for the fiscal year that ended in Sep. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2022 )	/	Revenue (A: Sep. 2022 )
	=	-0.427	/	0
	=	%

Pharmagreen Biotech's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0.008	/	0.001
	=	800.00 %

Pharmagreen Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.